← Back to Search

FDG and DHT PET Imaging for Prostate Cancer

N/A
Recruiting
Led By Michael Morris, M.D., Ph.D.
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will use PET scans with a radiotracer to see if it can more accurately find where prostate cancer has spread in the body.

Who is the study for?
Men with confirmed prostate cancer showing progression through new bone lesions, increased soft tissue disease, or rising PSA levels. They must have visible cancer signs on CT, MRI, or bone imaging and functionally adequate kidneys and liver. Those with severe kidney issues, past severe reactions to the PET scan tracers, or significant liver dysfunction cannot join.
What is being tested?
The trial is testing two PET scan radiotracers: [18F]-Fluoro-2-Deoxy-D-Glucose (FDG) and [18F] Dihydro-Testosterone (FDHT), to see if they can more accurately detect where prostate cancer has spread in the body compared to current methods.
What are the potential side effects?
Potential side effects may include allergic reactions to the tracers used for PET scans. However, since this study focuses on diagnostic procedures rather than treatment drugs, fewer side effects are expected compared to therapeutic trials.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
relationship between FDHT uptake and tissue analyses
relationship between FDHT uptake and tumor diffusivity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
\[18F\]-Fluoro-2-Deoxy-D-Glucose and -\[18F\] Dihydro-Testosterone

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,972 Previous Clinical Trials
597,428 Total Patients Enrolled
134 Trials studying Prostate Cancer
51,316 Patients Enrolled for Prostate Cancer
Michael Morris, M.D., Ph.D.Principal InvestigatorMemorial Sloan Kettering Cancer Center

Media Library

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Clinical Trial Eligibility Overview. Trial Name: NCT00588185 — N/A
Prostate Cancer Research Study Groups: 1
Prostate Cancer Clinical Trial 2023: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Highlights & Side Effects. Trial Name: NCT00588185 — N/A
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone 2023 Treatment Timeline for Medical Study. Trial Name: NCT00588185 — N/A
~15 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top